BiotechTube
MBX Biosciences

MBX Biosciences

MBX
United States
mbxbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

MBX · Stock Price

USD 34.71+23.60 (+212.42%)
Market Cap: $1.8B

Historical price data

Overview

MBX Biosciences is a clinical-stage biotechnology company focused on transforming the treatment landscape for endocrine and metabolic disorders through its proprietary Precision Endocrine Peptide (PEP) platform. Its lead candidate, canvuparatide (MBX 2109), is a potential once-weekly PTH replacement therapy for hypoparathyroidism, having completed Phase 2 trials with Phase 3 initiation planned for 2026. The company's strategy leverages advanced chemical modifications, programmable prodrug technology, and fatty acylation to overcome the inherent limitations of native peptide hormones, positioning it to capture value in underserved, high-need patient populations.

Endocrine DisordersMetabolic Disorders

Technology Platform

Proprietary Precision Endocrine Peptide (PEP) platform integrating advanced chemical modifications, programmable prodrug technology, and fatty acylation to transform native peptide hormones into therapeutics with optimized pharmacokinetics, extended half-life, and convenient dosing.

Pipeline

7
7 drugs in pipeline
DrugIndicationStageWatch
MBX 2109HypoparathyroidismPhase 2
400 µg of MBX 2109 once-weekly by subcutaneous injection + 2...HypoparathyroidismPhase 2
MBX 1416 (INN imapextide)Postbariatric HypoglycemiaPhase 2
MBX 2109 (Part A) + MBX 2109 (Part B) + PlaceboHealthyPhase 1
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109Renal ImpairmentPhase 1

Funding History

5
Total raised:$332.5M
PIPE$63.5M
IPOUndisclosed
Series A$115M
Series B$115M

Opportunities

MBX's lead program targets a rare disease (hypoparathyroidism) with a complete unmet need following the withdrawal of the only approved hormone replacement therapy, creating a clear regulatory and commercial pathway.
The proprietary PEP platform is extensible to large, validated markets in endocrinology and metabolism, such as diabetes and obesity, offering significant long-term pipeline potential.

Risk Factors

The company faces high clinical risk as its lead candidate must succeed in pivotal Phase 3 trials.
As a pre-revenue public company, it will require substantial additional capital to fund these trials, posing significant dilution risk to shareholders.
Commercial success also depends on market adoption in a rare disease landscape and potential future competition.

Competitive Landscape

In hypoparathyroidism, MBX's canvuparatide would compete against the burdensome standard of care (calcium/vitamin D) in a market with no currently approved hormone replacement therapy. Broader competition comes from large biopharma with peptide expertise, but MBX differentiates through its specialized, integrated platform focused on optimizing the pharmacokinetic profiles of endocrine hormones.

More companies in Biologics / Biosimilars →More companies in United States →